Skip to main content
. 2021 Jun 10;125(5):725–733. doi: 10.1038/s41416-021-01431-9

Fig. 2. Result of biomarkers for prediction of progression at 12-weeks evaluation.

Fig. 2

Prediction of progression according to (a) 0.05 threshold CEA kinetics value previously identified (primary endpoint), (b) baseline circulating marker median value and (c) kinetics circulating marker median value. CA19-9, carbohydrate antigen 19-9; CEA, Carcinoembryonic antigen; cfDNA, cell-free DNA; CTC, circulating tumour cells; ctDNA, circulating tumour DNA; L-, likelihood negative ratio; L+, likelihood positive ratio; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; Se, sensitivity; Sp, specificity.